Mereo BioPharma Group plc

NasdaqCM:MREO Stok Raporu

Piyasa değeri: US$657.4m

Mereo BioPharma Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Mereo BioPharma Group has been growing earnings at an average annual rate of 29.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 4.6% per year.

Anahtar bilgiler

29.1%

Kazanç büyüme oranı

59.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı4.6%
Özkaynak getirisi-46.8%
Net Marj-3,684.7%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Nov 25
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Oct 17

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Oct 03

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

Gelir ve Gider Dağılımı

Mereo BioPharma Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:MREO Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 241-372316
31 Mar 2410-261815
31 Dec 2310-291816
30 Sep 2310-322118
30 Jun 239-322419
31 Mar 230-422724
31 Dec 220-422628
30 Sep 220-312229
30 Jun 220-232033
31 Mar 2224-42133
31 Dec 2149172232
30 Sep 2149-102528
30 Jun 2150-373025
31 Mar 2125-1313023
31 Dec 200-2242922
30 Sep 200-1982524
30 Jun 200-1772125
31 Mar 200-1112027
31 Dec 190-462131
30 Sep 190-411829
30 Jun 190-401830
31 Mar 190-411730
31 Dec 180-411529
30 Sep 180-421530
30 Jun 180-441432
31 Mar 180-501541
31 Dec 170-521447
30 Sep 170-501447
30 Jun 170-471245
31 Mar 170-411337
31 Dec 160-351430
30 Jun 160-392223

Kaliteli Kazançlar: MREO is currently unprofitable.

Büyüyen Kar Marjı: MREO is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MREO is unprofitable, but has reduced losses over the past 5 years at a rate of 29.1% per year.

Büyüme Hızlandırma: Unable to compare MREO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: MREO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: MREO has a negative Return on Equity (-46.85%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin